Q3 Earnings Forecast for Immuneering Issued By HC Wainwright

Immuneering Corporation (NASDAQ:IMRX) – Analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Immuneering in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Immuneering’s Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.30) EPS, FY2029 earnings at ($1.32) EPS and FY2030 earnings at ($0.40) EPS.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.01).

IMRX has been the topic of a number of other research reports. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Cantor Fitzgerald initiated coverage on Immuneering in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price objective for the company. UBS Group set a $14.00 price objective on Immuneering in a report on Thursday. Needham & Company LLC increased their target price on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Chardan Capital upgraded Immuneering to a “strong-buy” rating in a report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Immuneering presently has an average rating of “Buy” and a consensus target price of $17.50.

Immuneering Stock Performance

Shares of IMRX stock opened at $4.53 on Monday. The firm has a market cap of $293.09 million, a P/E ratio of -4.36 and a beta of 0.43. The firm’s 50 day moving average price is $4.56 and its 200-day moving average price is $4.98. Immuneering has a one year low of $2.90 and a one year high of $10.08.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently bought and sold shares of the stock. Focus Financial Network Inc. purchased a new position in shares of Immuneering in the 2nd quarter valued at about $62,000. PVG Asset Management Corp purchased a new stake in shares of Immuneering during the first quarter worth approximately $773,000. Weiss Asset Management LP acquired a new stake in Immuneering in the first quarter valued at approximately $464,000. Cetera Investment Advisers acquired a new stake in Immuneering in the first quarter valued at approximately $67,000. Finally, Levin Capital Strategies L.P. purchased a new position in Immuneering in the first quarter worth approximately $53,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.